Literature DB >> 14754757

Hypoxia decreases expression of soluble guanylate cyclase in cultured rat pulmonary artery smooth muscle cells.

Paul M Hassoun1, Galina Filippov, Michael Fogel, Cameron Donaldson, Usamah S Kayyali, Larissa A Shimoda, Kenneth D Bloch.   

Abstract

Nitric oxide (NO) has an important role in modulating the pulmonary vascular tone. NO acts, in part, by stimulating soluble guanylate cyclase (sGC) to synthesize the intracellular second messenger cyclic GMP. In vascular smooth muscle cells, sGC is a heterodimer composed of alpha1 and beta1 subunits. The objective of this study was to test whether oxygen concentration regulates sGC expression in cultured rat pulmonary artery smooth muscle cells (rPaSMC). rPaSMC were exposed to 0, 3, and 20% oxygen for 1-48 h, and sGC subunit mRNA levels were measured. Compared with rPaSMC exposed to 20% oxygen, sGC alpha1 and beta1 subunit mRNA levels were markedly decreased in rPaSMC exposed to 0% and 3% oxygen. The decrease in sGC subunit mRNA levels in hypoxic rPaSMC was detected as early as 6 h of exposure. Compared with rPaSMC exposed to 20% oxygen, exposure of rPaSMC to 3% oxygen progressively decreased sGC subunit protein levels at 24 and 48 h. There was also a 30% and 50% decrease in sGC enzyme activity in cells exposed to hypoxia for 24 and 48 h (P < 0.05 and P < 0.001, respectively, as compared with cells maintained in normoxia). These results demonstrate that hypoxia decreases sGC expression in cultured pulmonary artery smooth muscle cells and suggest that, in hypoxic vascular smooth muscle, decreased cyclic GMP synthesis may limit the vasodilator response to NO.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754757     DOI: 10.1165/rcmb.2003-0287OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  8 in total

1.  Regulation of soluble guanylyl cyclase-alpha1 expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR.

Authors:  Sergio de Frutos; Carlos H Nitta; Elizabeth Caldwell; Jessica Friedman; Laura V González Bosc
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-10       Impact factor: 5.464

2.  Heme oxygenase-1 induction depletes heme and attenuates pulmonary artery relaxation and guanylate cyclase activation by nitric oxide.

Authors:  Christopher J Mingone; Mansoor Ahmad; Sachin A Gupte; Joseph L Chow; Michael S Wolin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-04       Impact factor: 4.733

3.  Relative sensitivity of soluble guanylate cyclase and mitochondrial respiration to endogenous nitric oxide at physiological oxygen concentration.

Authors:  Félix Rodríguez-Juárez; Enara Aguirre; Susana Cadenas
Journal:  Biochem J       Date:  2007-07-15       Impact factor: 3.857

4.  Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.

Authors:  Masahiko Oka; Vijaya Karoor; Noriyuki Homma; Tetsutaro Nagaoka; Eiko Sakao; Scott M Golembeski; Jennifer Limbird; Masatoshi Imamura; Sarah A Gebb; Karen A Fagan; Ivan F McMurtry
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

Review 5.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

6.  In Vitro Model for Ischemic Stroke: Functional Analysis of Vascular Smooth Muscle Cells.

Authors:  Melissa Mariana; Claudio Roque; Graça Baltazar; Elisa Cairrao
Journal:  Cell Mol Neurobiol       Date:  2021-05-25       Impact factor: 4.231

7.  Characterization of the human alpha1 beta1 soluble guanylyl cyclase promoter: key role for NF-kappaB(p50) and CCAAT-binding factors in regulating expression of the nitric oxide receptor.

Authors:  Martín L Marro; Concepción Peiró; Catherine M Panayiotou; Reshma S Baliga; Sabine Meurer; Harald H H W Schmidt; Adrian J Hobbs
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

Review 8.  Modulating cGMP to treat lung diseases.

Authors:  Hossein-Ardeschir Ghofrani; Friedrich Grimminger
Journal:  Handb Exp Pharmacol       Date:  2009
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.